102 related articles for article (PubMed ID: 9154112)
1. The in vitro biological activities of synthetic 18-O-methyl mycalamide B, 10-epi-18-O-methyl mycalamide B and pederin.
Richter A; Kocienski P; Raubo P; Davies DE
Anticancer Drug Des; 1997 Apr; 12(3):217-27. PubMed ID: 9154112
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
3. Pederin-type pathways of uncultivated bacterial symbionts: analysis of o-methyltransferases and generation of a biosynthetic hybrid.
Zimmermann K; Engeser M; Blunt JW; Munro MH; Piel J
J Am Chem Soc; 2009 Mar; 131(8):2780-1. PubMed ID: 19206228
[TBL] [Abstract][Full Text] [Related]
4. Isolation, biological activity, synthesis, and medicinal chemistry of the pederin/mycalamide family of natural products.
Mosey RA; Floreancig PE
Nat Prod Rep; 2012 Sep; 29(9):980-95. PubMed ID: 22772477
[TBL] [Abstract][Full Text] [Related]
5. Mycalamides, pederin and psymberin as natural carbohydrates and potential antitumor agents: past and future perspectives.
Witczak ZJ; Rampulla RM; Bommareddy A
Mini Rev Med Chem; 2012 Dec; 12(14):1520-32. PubMed ID: 22827176
[TBL] [Abstract][Full Text] [Related]
6. Mycalamide D, a new cytotoxic amide from the New Zealand marine sponge Mycale species.
West LM; Northcote PT; Hood KA; Miller JH; Page MJ
J Nat Prod; 2000 May; 63(5):707-9. PubMed ID: 10843597
[TBL] [Abstract][Full Text] [Related]
7. The protein synthesis inhibitors mycalamides A and E have limited susceptibility toward the drug efflux network.
Venturi V; Davies C; Singh AJ; Matthews JH; Bellows DS; Northcote PT; Keyzers RA; Teesdale-Spittle PH
J Biochem Mol Toxicol; 2012 Mar; 26(3):94-100. PubMed ID: 22162108
[TBL] [Abstract][Full Text] [Related]
8. Change of ras-transformed NRK-cells back to normal morphology by mycalamides A and B, antitumor agents from a marine sponge.
Ogawara H; Higashi K; Uchino K; Perry NB
Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2152-4. PubMed ID: 1797440
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of psymberin analogues: probing a functional correlation with the pederin/mycalamide family of natural products.
Jiang X; Williams N; De Brabander JK
Org Lett; 2007 Jan; 9(2):227-30. PubMed ID: 17217271
[TBL] [Abstract][Full Text] [Related]
10. Mycalamides C and D, cytotoxic compounds from the marine sponge Stylinos n. species.
Simpson JS; Garson MJ; Blunt JW; Munro MH; Hooper JN
J Nat Prod; 2000 May; 63(5):704-6. PubMed ID: 10843596
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis of mycalamide A.
Sohn JH; Waizumi N; Zhong HM; Rawal VH
J Am Chem Soc; 2005 May; 127(20):7290-1. PubMed ID: 15898759
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
[TBL] [Abstract][Full Text] [Related]
13. A formal synthesis of (-)-mycalamide A.
Trost BM; Yang H; Probst GD
J Am Chem Soc; 2004 Jan; 126(1):48-9. PubMed ID: 14709053
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Psymberin, a potent sponge-derived cytotoxin from Psammocinia distantly related to the pederin family.
Cichewicz RH; Valeriote FA; Crews P
Org Lett; 2004 Jun; 6(12):1951-4. PubMed ID: 15176791
[TBL] [Abstract][Full Text] [Related]
16. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides.
Zhang X; Minale L; Zampella A; Smith CD
Cancer Res; 1997 Sep; 57(17):3751-8. PubMed ID: 9288783
[TBL] [Abstract][Full Text] [Related]
17. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
18. Total synthesis of (+)-mycalamide A.
Kagawa N; Ihara M; Toyota M
Org Lett; 2006 Mar; 8(5):875-8. PubMed ID: 16494463
[TBL] [Abstract][Full Text] [Related]
19. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent.
Liu J; Towle MJ; Cheng H; Saxton P; Reardon C; Wu J; Murphy EA; Kuznetsov G; Johannes CW; Tremblay MR; Zhao H; Pesant M; Fang FG; Vermeulen MW; Gallagher BM; Littlefield BA
Anticancer Res; 2007; 27(3B):1509-18. PubMed ID: 17595769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
